NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its second quarter financial results on August 11, 2022, after market close. The company focuses on improving the lives of individuals with epilepsy through its innovative RNS System, the first of its kind designed to provide real-time treatment at the seizure source. A conference call will follow at 1:30 PM PT, with a link available for investors to listen. Archived recordings will be accessible on the company’s website for at least 90 days.

Positive

• Developed the RNS System, a brain-responsive platform for personalized epilepsy treatment.
• First commercially available system targeting drug-resistant epilepsy.

Negative

• None.

MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 11, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

• Webcast link for interested listeners:
  • https://edge.media-server.com/mmc/p/e9g3pw5c [edge.media-server.com] [nam12.safelinks.protection.outlook.com]
• Dial-in registration for sell-side research analysts:
  • https://register.vevent.com/register/BI9a39528014b64663b5d4f5d3f7805954

Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com.

An archived recording will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcasts will be available for replay for at least 90 days after the event.

About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
investors@neuropace.com 

FAQ

When will NeuroPace report its financial results for Q2 2022?

NeuroPace will report its Q2 2022 financial results on August 11, 2022, after market close.

What is the significance of the RNS System by NeuroPace?

The RNS System is the first commercial device that provides personalized, real-time treatment for epilepsy, targeting seizure sources.

How can I listen to NeuroPace's Q2 2022 conference call?

The conference call can be accessed through a webcast link provided in the press release, starting at 1:30 PM PT on August 11, 2022.

Where can I find the archived recording of NeuroPace's conference call?

The archived recording will be available in the 'Investors' section of NeuroPace's website for at least 90 days after the event.